Matches in Nanopublications for { ?s ?p "[In contrast to rare mutations in stomach adenocarcinomas, a high frequency of CDKN2 mutations was identified in other 3 cancers, 11 of 20 (55%) lung cancers (7 of 10 NSCLCs and 4 of 10 SCLCs), 14 of 20 (70%) cervix cancers and 11 of 20 (55%) hepatocellular carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- NP624261.RADdQka6J0NlJ1vATPCK3ehWnhvn_U_YttJk1a0uC35lI130_assertion description "[In contrast to rare mutations in stomach adenocarcinomas, a high frequency of CDKN2 mutations was identified in other 3 cancers, 11 of 20 (55%) lung cancers (7 of 10 NSCLCs and 4 of 10 SCLCs), 14 of 20 (70%) cervix cancers and 11 of 20 (55%) hepatocellular carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP624261.RADdQka6J0NlJ1vATPCK3ehWnhvn_U_YttJk1a0uC35lI130_provenance.
- NP917276.RAYFG4w_6gu8Wy53kqZngVxEEDNWsLU7cujOES9DroTRA130_assertion description "[In contrast to rare mutations in stomach adenocarcinomas, a high frequency of CDKN2 mutations was identified in other 3 cancers, 11 of 20 (55%) lung cancers (7 of 10 NSCLCs and 4 of 10 SCLCs), 14 of 20 (70%) cervix cancers and 11 of 20 (55%) hepatocellular carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP917276.RAYFG4w_6gu8Wy53kqZngVxEEDNWsLU7cujOES9DroTRA130_provenance.
- NP261323.RA_HquGgXybCogko2vwZgvCf6DStzeV0UGcbWsWZ1VEgE130_assertion description "[In contrast to rare mutations in stomach adenocarcinomas, a high frequency of CDKN2 mutations was identified in other 3 cancers, 11 of 20 (55%) lung cancers (7 of 10 NSCLCs and 4 of 10 SCLCs), 14 of 20 (70%) cervix cancers and 11 of 20 (55%) hepatocellular carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP261323.RA_HquGgXybCogko2vwZgvCf6DStzeV0UGcbWsWZ1VEgE130_provenance.
- assertion description "[In contrast to rare mutations in stomach adenocarcinomas, a high frequency of CDKN2 mutations was identified in other 3 cancers, 11 of 20 (55%) lung cancers (7 of 10 NSCLCs and 4 of 10 SCLCs), 14 of 20 (70%) cervix cancers and 11 of 20 (55%) hepatocellular carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[In contrast to rare mutations in stomach adenocarcinomas, a high frequency of CDKN2 mutations was identified in other 3 cancers, 11 of 20 (55%) lung cancers (7 of 10 NSCLCs and 4 of 10 SCLCs), 14 of 20 (70%) cervix cancers and 11 of 20 (55%) hepatocellular carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[In contrast to rare mutations in stomach adenocarcinomas, a high frequency of CDKN2 mutations was identified in other 3 cancers, 11 of 20 (55%) lung cancers (7 of 10 NSCLCs and 4 of 10 SCLCs), 14 of 20 (70%) cervix cancers and 11 of 20 (55%) hepatocellular carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[In contrast to rare mutations in stomach adenocarcinomas, a high frequency of CDKN2 mutations was identified in other 3 cancers, 11 of 20 (55%) lung cancers (7 of 10 NSCLCs and 4 of 10 SCLCs), 14 of 20 (70%) cervix cancers and 11 of 20 (55%) hepatocellular carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[In contrast to rare mutations in stomach adenocarcinomas, a high frequency of CDKN2 mutations was identified in other 3 cancers, 11 of 20 (55%) lung cancers (7 of 10 NSCLCs and 4 of 10 SCLCs), 14 of 20 (70%) cervix cancers and 11 of 20 (55%) hepatocellular carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[In contrast to rare mutations in stomach adenocarcinomas, a high frequency of CDKN2 mutations was identified in other 3 cancers, 11 of 20 (55%) lung cancers (7 of 10 NSCLCs and 4 of 10 SCLCs), 14 of 20 (70%) cervix cancers and 11 of 20 (55%) hepatocellular carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP300889.RADbUi2hDITks6pSqs7NIzeQgOsy-h2cwDvNDl-cbqdEU130_assertion description "[In contrast to rare mutations in stomach adenocarcinomas, a high frequency of CDKN2 mutations was identified in other 3 cancers, 11 of 20 (55%) lung cancers (7 of 10 NSCLCs and 4 of 10 SCLCs), 14 of 20 (70%) cervix cancers and 11 of 20 (55%) hepatocellular carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP300889.RADbUi2hDITks6pSqs7NIzeQgOsy-h2cwDvNDl-cbqdEU130_provenance.
- NP1412063.RAs2v235ngODdDrQdpedko5pYIUm0wRCp5ZlMHMBjLD9E130_assertion description "[In contrast to rare mutations in stomach adenocarcinomas, a high frequency of CDKN2 mutations was identified in other 3 cancers, 11 of 20 (55%) lung cancers (7 of 10 NSCLCs and 4 of 10 SCLCs), 14 of 20 (70%) cervix cancers and 11 of 20 (55%) hepatocellular carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1412063.RAs2v235ngODdDrQdpedko5pYIUm0wRCp5ZlMHMBjLD9E130_provenance.
- NP1412058.RA9psowKpoZ8fZTb3acF6AGxJKCgThXtStOatlz_dw2RU130_assertion description "[In contrast to rare mutations in stomach adenocarcinomas, a high frequency of CDKN2 mutations was identified in other 3 cancers, 11 of 20 (55%) lung cancers (7 of 10 NSCLCs and 4 of 10 SCLCs), 14 of 20 (70%) cervix cancers and 11 of 20 (55%) hepatocellular carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1412058.RA9psowKpoZ8fZTb3acF6AGxJKCgThXtStOatlz_dw2RU130_provenance.